

Chronic Kidney Disease Excellence Exchange Agenda

(Confirmed) EUCAN Series 1: Monday 19th April & Monday 26th April – 17:00 GMT

(Proposed) INTL Series 1: May 10th – 25th

(Proposed) China Series 1: June 11th – 26th

(Proposed) EUCAN Series 2: August 20th – 21st & September 6th – 18th

(Proposed) INTL Series 2: October 8th – 23rd

(Proposed) Japan Series 2: November 26th – 27th & December 3rd – 11th

Objectives

This series of chronic kidney disease (CKD) excellence exchange meetings will aim to:

- Provide a forum for invited healthcare professionals (HCPs) to participate in scientific exchange with their peers around the practicalities of current and future approaches for the treatment and prevention of CKD, with a focus on new therapeutic agents and diagnostics
- Provide an opportunity for physicians to exchange personal views on the current treatment and prevention of CKD progression, and discuss the unmet clinical needs in their regions
- Discuss and debate the potential impact of novel kidney outcome studies, in both diabetic and nondiabetic kidney disease, on the future treatment and prevention of CKD
- Discuss the potential impact of upcoming clinical trials in the CKD field

Day 1: Current treatment landscape for CKD

Total run time: 3 hours, 15 minutes (including 5 minute break)

Time (min)	Discussion Session	Discussion lead	Presentation (min)	Discussion (min)
15	<i>Log in</i>			
5	Welcome by AstraZeneca, chair and faculty introductions			
15	Scene-setting ice-breaker – Interactive session to establish the delegates' insights into the burden of CKD in their clinics and challenges associated with managing CKD • Identify the typical characteristics of CKD patients treated in the delegate's clinics • Discuss the challenges involved in the day-to-day management of CKD • Discuss the unmet needs within the current CKD treatment landscape and any residual risk following the use of current therapies	Hiddo Heerspink David Wheeler	5	10
30	Novel therapies for CKD – SGLT2 inhibitors • Discuss kidney outcomes data from recent SGLT2 inhibitor kidney and cardiovascular outcomes studies	Hiddo Heerspink David Wheeler	15	15

This non-promotional scientific exchange meeting has been organized and funded by AstraZeneca.

Veeva ID No.: Z3-0411 Date of Prep: March 2021

	- Summarize the study design, results, and subanalyses of the DAPA-CKD trial - Debate the role of SGLT2 inhibitors in the current CKD care pathway and whether this will change following the results from DAPA-CKD, CREDENCE, and other cardiorenal outcomes trials			
20	Novel therapies for CKD – MRAs - Summarize the study design and primary results of the FIDELIO-DKD trial - Debate the role of mineralocorticoid receptor antagonists (MRAs) in the current CKD care pathway and whether this will change following the results from FIDELIO-DKD	Peter Rossing (TBC)	10	10
20	Workshop 1 <i>Delegates to break out into two workshop sessions led by the faculty presenters from the previous two sessions. Leverage prespecified polling questions based around the recent trial results to stimulate wider discussion led by the faculty presenters</i>	David Cherney (TBC) Hiddo Heerspink Peter Rossing (TBC) Katherine Tuttle (TBC) David Wheeler	0	20
5	Break			
20	Using SGLT2 inhibitors and MRAs in the clinic – practical considerations - Discuss the key patient populations who might benefit most from treatment with SGLT2 inhibitors and MRAs - Discuss the potential barriers and safety concerns associated with using SGLT2 inhibitors and MRAs in CKD, and explore the available data related to these concerns - Debate what should be discussed with patients prior to initiation of an SGLT2 inhibitor or MRA	David Cherney (TBC)	10	10
20	Optimal medical therapy for CKD - Debate optimal medical therapies for CKD patients - Discuss circumstances in which RAS inhibition should be initiated or suspended, and thus how to layer therapies most effectively - Discuss complications and scenarios in which optimal medical therapy should be deviated from	Katherine Tuttle (TBC)	10	10
30	Workshop 2 <i>Delegates to break out into two workshop sessions led by the faculty presenters from the previous two sessions. Faculty to present patient case and discuss with delegates the practical considerations for optimizing the patients' therapy in light of the discussions held in previous sessions</i>	David Cherney (TBC) Hiddo Heerspink Peter Rossing (TBC) Katherine Tuttle (TBC) David Wheeler	0	30

This non-promotional scientific exchange meeting has been organized and funded by AstraZeneca.
Veeva ID No.: Z3-0411 Date of Prep: March 2021

20	What is in the pipeline for CKD? - Summarize the ongoing outcome trials in CKD - Discuss ongoing studies investigating combination therapies in CKD - Debate how these trials might change patient management and guidelines across CKD stages	Hiddo Heerspink	10	10
10	Discussion session, summary, and close	All	0	10

Day 2: Optimal management and considerations for CKD

Total run time: 3 hours, 15 minutes (including 5 minute break)

Time	Discussion Session	Discussion lead	Presentation (min)	Discussion (min)
10	<i>Log in</i>			
5	Welcome to day 2 and faculty introductions			
20	Managing and optimizing the patient pathway – Early screening, diagnosis, and intervention - Discuss the importance of early screening, diagnosis, and intervention in CKD - Outline barriers to the early diagnosis of CKD and how best to overcome these barriers - Discuss the role of nephrologists in educating primary care physicians on the importance of early CKD identification and intervention - Debate how early screening, diagnosis, and intervention will impact patients with CKD in the future	Roberto Pecoits-Filho (TBC)	10	10
20	Managing and optimizing the patient pathway – Multidisciplinary collaboration and barriers to treatment - Discuss the importance of multidisciplinary collaboration and how to establish and optimize effective collaborations for the management of CKD patients <i>Debate when these collaborations would be most crucial from a nephrology perspective</i> - Discuss the main barriers to the treatment of CKD patients <i>Debate whether the delegates' local healthcare systems allow for optimal management of patients with CKD</i> - Identify differences between inpatient and outpatient care and discuss how to bridge the gap	Pam Kushner (TBC)	10	10

This non-promotional scientific exchange meeting has been organized and funded by AstraZeneca.
Veeva ID No.: Z3-0411 Date of Prep: March 2021

	between them • Debate how to improve outpatient monitoring and patient quality of life			
30	Workshop 1 <i>Delegates to break out into two workshop sessions. Two prespecified delegates to present slides on the CKD patient pathway in their country and discuss with other delegates the regional differences in patient pathways, how patient pathways could be improved, and how to achieve these improvements</i>	Hiddo Heerspink Pam Kushner (TBC) John McMurray (TBC) Roberto Pecoits-Filho (TBC) David Wheeler TBC	0	30
5	Break			
20	Managing CKD with cardiovascular comorbidities • Identify important treatment considerations for managing CKD patients with, or at risk of, CVD • Outline differences in the management of CKD patients with and without diabetes • Discuss when and why nephrologists should communicate with cardiologists	John McMurray (TBC)	10	10
20	Optimal approaches and considerations in dialysis and transplantation • Discuss important considerations when recommending a patient for dialysis or kidney transplant – <i>Discuss the use of novel CKD therapies in patients with ESKD</i> • Discuss monitoring electrolyte imbalances in patients undergoing dialysis treatment – <i>Discuss managing complications, such as hyperkalemia and anemia, when transitioning an ESKD patient to dialysis</i> • Discuss how cardiovascular risk and diabetic status may influence dialysis and transplant decisions	TBC <i>Suggested:</i> <i>Connie Rhee</i> <i>Kerri L Cavanaugh</i>	10	10
40	Workshop 2 <i>Delegates to break out into two workshop sessions, one on managing CKD with cardiovascular comorbidities and the other on the optimal approaches and considerations in dialysis and transplantation. Each workshop will be led by the relevant faculty presenter from the previous two sessions.</i> <i>CKD with CVD workshop – faculty to present a patient case and discuss with delegates the practical considerations and optimal medical therapy for this patient.</i> <i>Dialysis and transplantation workshop – delegates to be presented with the key perceived challenges to managing dialysis patients and discuss how to address these challenges.</i>	Hiddo Heerspink Pam Kushner (TBC) John McMurray (TBC) Roberto Pecoits-Filho (TBC) David Wheeler TBC	0	40

This non-promotional scientific exchange meeting has been organized and funded by AstraZeneca.
 Veeva ID No.: Z3-0411 Date of Prep: March 2021

	<i>Faculty presenters to change workshops after 20 minutes so that delegates take part in both workshops</i>			
25	What does the future hold for CKD? • Discuss pharmacological and non-pharmacological innovations currently in development that could transform the future of CKD – <i>Discuss the possible implications of novel biomarkers, precision medications, and at-home measurement and dialysis devices</i> • Debate how these innovations will impact patients with CKD in the future	TBC	10	15
10	Discussion session, summary, and close	All	0	10

This non-promotional scientific exchange meeting has been organized and funded by AstraZeneca.
Veeva ID No.: Z3-0411 Date of Prep: March 2021